NRL-1049

Overview

NRL-1049 (BA-1049 (free base)) is an orally available and selective ROCK2 inhibitor with IC 50 values of 0.59 µM for ROCK2 and 26 µM for ROCK1 , respectively. NRL-1049 modulates ROCK signaling, preserves blood-brain barrier integrity, reduces edema, seizures and hemorrhage, and alleviates cerebral cavernous malformation lesion burden. NRL-1049 can be used for the study of acute brain injury, ischemic stroke, and cerebral cavernous malformations.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Cytoskeleton | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > ROCK

Product Information

• Catalog No.: HY-162596
• CAS No.: 1973494-16-4
• Molecular Formula: C16H21N3O2S
• Molecular Weight: 319.42
• Purity: 99.96%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source